Lavybens Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Lavybens Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, g…

2012-12-03 Hyderabad, Telangana Active Unlisted Active Compliant
Share
LP Lavybens Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Lavybens Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
77/100
Trust Score
Low Risk

Lavybens Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 77/100. Lavybens Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2012, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Lavybens Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
77/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
50/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 60/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 75/100 Low Risk
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2023 - filings overdue.
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
VENKATA PRABHAKARA RAO PECHETTI 01234567 Director 01/04/2018 6 yrs Approved
SRINIVASU VALLEM 01234567 Director 01/04/2018 6 yrs Approved
HIMABINDU YELLA 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2016)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2020 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 50 · Distress 55
Growth signals & trust indicators
Asset base grew 1.42 - capacity expansion.
Net margin improved to 2.1x.
Operating for 13+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Profit declined two years in a row.
Statutory filings appear overdue.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence70/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment67/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view64/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 6 events
30 Sep 2023
Last AGM held
Annual general meeting
31 Mar 2023
Latest balance sheet
Filed with ROC
03 Dec 2012
Incorporated
Registered with Roc Hyderabad
Director appointed
VENKATA PRABHAKARA RAO PECHETTI (Director)
Director appointed
SRINIVASU VALLEM (Director)
Director appointed
HIMABINDU YELLA (Director)
10

Key Observations

Auto-generated from the data above
Revenue declined 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2020 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Kromaspects Scitec Solutions Private Limited U72900KA2002PTC030702 Bangalore., Karnataka, India
Emprocell Clinical Research Private Limited U24231MH2006PTC161334 Navi Mumbai, Maharashtra, India
Aashraya Technologies Private Limited U73100KA2012PTC064058 Bangalore, Karnataka, India
Buildsworth Solutions Private Limited U74999UP2017PTC094289 Ghaziabad, Uttar Pradesh, India
Intent Design India Private Limited U72200KA2011PTC059375 Bangalore, Karnataka, India
Acme Progen Biotech (India) Private Limited U33111TZ2007PTC013847 Salem, Tamil Nadu, India
Magna-Opus Solutions Private Limited U74999MH2013PTC251109 Mumbai, Maharashtra, India
Orac Lifesciences Private Limited U24239MH2006PTC165772 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Lavybens Pharmaceuticals Private Limited before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Lavybens Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 50/100, margin trends, ownership structure and peer set for Lavybens Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 77/100, distress signals and MSME payment-delay disclosures - know whether Lavybens Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Lavybens Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Lavybens Pharmaceuticals Private Limited an active company?

Lavybens Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 75/100 (Low Risk).

Is Lavybens Pharmaceuticals Private Limited financially healthy?

Lavybens Pharmaceuticals Private Limited has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.

Should I do business with Lavybens Pharmaceuticals Private Limited?

Its overall Trust Score is 77/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Lavybens Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Lavybens Pharmaceuticals Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Lavybens Pharmaceuticals Private Limited up to date with its ROC filings?

Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 75/100 (Low Risk).

Is it risky to lend to Lavybens Pharmaceuticals Private Limited?

Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.